Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2018 Aug 21. doi: 10.1038/s41375-018-0239-1. [Epub ahead of print]

PMID:
30131584
2.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
3.

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.

Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M.

Sci Rep. 2018 Apr 18;8(1):6220. doi: 10.1038/s41598-018-24437-5.

4.

Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.

Rohr-Udilova N, Bauer E, Timelthaler G, Eferl R, Stolze K, Pinter M, Seif M, Hayden H, Reiberger T, Schulte-Hermann R, Peck-Radosavljevic M, Stoiber D, Trauner M.

Oncotarget. 2018 Jan 22;9(11):10054-10068. doi: 10.18632/oncotarget.24300. eCollection 2018 Feb 9.

5.

STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer.

Crnčec I, Modak M, Gordziel C, Svinka J, Scharf I, Moritsch S, Pathria P, Schlederer M, Kenner L, Timelthaler G, Müller M, Strobl B, Casanova E, Bayer E, Mohr T, Stöckl J, Friedrich K, Eferl R.

Mol Oncol. 2018 Apr;12(4):514-528. doi: 10.1002/1878-0261.12178. Epub 2018 Feb 20.

6.

AKT3 drives adenoid cystic carcinoma development in salivary glands.

Zboray K, Mohrherr J, Stiedl P, Pranz K, Wandruszka L, Grabner B, Eferl R, Moriggl R, Stoiber D, Sakamoto K, Wagner KU, Popper H, Casanova E, Moll HP.

Cancer Med. 2018 Feb;7(2):445-453. doi: 10.1002/cam4.1293. Epub 2017 Dec 28.

7.

Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression.

Kramer N, Schmöllerl J, Unger C, Nivarthi H, Rudisch A, Unterleuthner D, Scherzer M, Riedl A, Artaker M, Crncec I, Lenhardt D, Schwarz T, Prieler B, Han X, Hengstschläger M, Schüler J, Eferl R, Moriggl R, Sommergruber W, Dolznig H.

Oncogene. 2017 Sep 28;36(39):5460-5472. doi: 10.1038/onc.2017.144. Epub 2017 May 29.

PMID:
28553956
8.

Chromosomal instability in HCC: a key function for checkpoint kinase 2.

Eferl R, Trauner M.

Gut. 2018 Feb;67(2):204-205. doi: 10.1136/gutjnl-2017-314101. Epub 2017 May 5. No abstract available.

PMID:
28476916
9.

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, Diamanti MA, Linder M, Timelthaler G, Dienes HP, Kenner L, Wrba F, Prager GW, Rose-John S, Eferl R, Liguori G, Botti G, Martinelli E, Greten FR, Ciardiello F, Sibilia M.

Gastroenterology. 2017 Jul;153(1):178-190.e10. doi: 10.1053/j.gastro.2017.03.053. Epub 2017 Apr 9.

10.

CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?

Calvisi D, Eferl R.

Gut. 2017 Jul;66(7):1179-1180. doi: 10.1136/gutjnl-2016-313547. Epub 2017 Jan 5. No abstract available.

PMID:
28057692
11.

Generation of metastatic melanoma specific antibodies by affinity purification.

Schütz B, Koppensteiner A, Schörghofer D, Kinslechner K, Timelthaler G, Eferl R, Hengstschläger M, Missbichler A, Hundsberger H, Mikula M.

Sci Rep. 2016 Nov 17;6:37253. doi: 10.1038/srep37253.

12.

Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.

Kuttke M, Sahin E, Pisoni J, Percig S, Vogel A, Kraemmer D, Hanzl L, Brunner JS, Paar H, Soukup K, Halfmann A, Dohnal AM, Steiner CW, Blüml S, Basilio J, Hochreiter B, Salzmann M, Hoesel B, Lametschwandtner G, Eferl R, Schmid JA, Schabbauer G.

Oncoimmunology. 2016 Mar 28;5(7):e1164918. doi: 10.1080/2162402X.2016.1164918. eCollection 2016 Jul.

13.

Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis.

Svinka J, Pflügler S, Mair M, Marschall HU, Hengstler JG, Stiedl P, Poli V, Casanova E, Timelthaler G, Sibilia M, Eferl R.

J Mol Med (Berl). 2017 Jan;95(1):109-117. doi: 10.1007/s00109-016-1462-8. Epub 2016 Aug 27.

14.

Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Oct 26;6:8802. doi: 10.1038/ncomms9802. No abstract available.

PMID:
26499136
15.

STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Jul 22;6:7736. doi: 10.1038/ncomms8736. Erratum in: Nat Commun. 2015;6:8802.

16.

Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice.

Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, Hoffmann T, Filipits M, Berger W, Poli V, Kenner L, Bilban M, Casanova E, Müller M, Strobl B, Bayer E, Mohr T, Sexl V, Eferl R.

Oncoimmunology. 2015 Jan 22;4(4):e998529. eCollection 2015 Apr.

17.

Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Győrffy B, Penninger JM, Popper H, Casanova E.

Nat Commun. 2015 Mar 3;6:6285. doi: 10.1038/ncomms7285.

18.

Induction of colorectal cancer in mice and histomorphometric evaluation of tumors.

Crncec I, Pathria P, Svinka J, Eferl R.

Methods Mol Biol. 2015;1267:145-64. doi: 10.1007/978-1-4939-2297-0_7.

PMID:
25636468
19.

Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation.

Hefetz-Sela S, Stein I, Klieger Y, Porat R, Sade-Feldman M, Zreik F, Nagler A, Pappo O, Quagliata L, Dazert E, Eferl R, Terracciano L, Wagner EF, Ben-Neriah Y, Baniyash M, Pikarsky E.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17582-7. doi: 10.1073/pnas.1409700111. Epub 2014 Nov 24.

20.

STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer models.

Marino F, Orecchia V, Regis G, Musteanu M, Tassone B, Jon C, Forni M, Calautti E, Chiarle R, Eferl R, Poli V.

Am J Cancer Res. 2014 Sep 6;4(5):484-94. eCollection 2014.

21.

Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis.

Stiedl P, McMahon R, Blaas L, Stanek V, Svinka J, Grabner B, Zollner G, Kessler SM, Claudel T, Müller M, Mikulits W, Bilban M, Esterbauer H, Eferl R, Haybaeck J, Trauner M, Casanova E.

Hepatology. 2015 Feb;61(2):613-26. doi: 10.1002/hep.27408.

22.

Inducible, dose-adjustable and time-restricted reconstitution of STAT1 deficiency in vivo.

Leitner NR, Lassnig C, Rom R, Heider S, Bago-Horvath Z, Eferl R, Müller S, Kolbe T, Kenner L, Rülicke T, Strobl B, Müller M.

PLoS One. 2014 Jan 29;9(1):e86608. doi: 10.1371/journal.pone.0086608. eCollection 2014.

23.

Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin.

Evstatiev R, Bukaty A, Jimenez K, Kulnigg-Dabsch S, Surman L, Schmid W, Eferl R, Lippert K, Scheiber-Mojdehkar B, Kvasnicka HM, Khare V, Gasche C.

Am J Hematol. 2014 May;89(5):524-9. doi: 10.1002/ajh.23682. Epub 2014 Feb 24.

24.

STAT3 in hepatocellular carcinoma: new perspectives.

Svinka J, Mikulits W, Eferl R.

Hepat Oncol. 2014 Jan;1(1):107-120. doi: 10.2217/hep.13.7. Epub 2013 Dec 20. Review.

25.

Meprin β, a novel mediator of vascular remodelling underlying pulmonary hypertension.

Biasin V, Marsh LM, Egemnazarov B, Wilhelm J, Ghanim B, Klepetko W, Wygrecka M, Olschewski H, Eferl R, Olschewski A, Kwapiszewska G.

J Pathol. 2014 May;233(1):7-17. doi: 10.1002/path.4303. Epub 2014 Jan 31.

PMID:
24258247
26.

p21Waf1/Cip1 revisited: oncogenic function in hepatocellular carcinoma.

Goldenberg D, Eferl R.

Gut. 2014 Sep;63(9):1372-3. doi: 10.1136/gutjnl-2013-306343. Epub 2013 Nov 12. No abstract available.

PMID:
24221458
27.

CCL2 at the crossroad of cancer metastasis.

Eferl R.

JAKSTAT. 2013 Apr 1;2(2):e23816. doi: 10.4161/jkst.23816.

28.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14.

29.

NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development.

Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernández-Rodriguez CM, Pinedo F, Huber H, Eferl R, Mikulits W, Fabregat I.

PLoS One. 2012;7(9):e45285. doi: 10.1371/journal.pone.0045285. Epub 2012 Sep 26.

30.

A dual role for interferon γ signalling in hepatocellular carcinoma.

Eferl R.

J Hepatol. 2012 Nov;57(5):940-2. doi: 10.1016/j.jhep.2012.07.040. Epub 2012 Aug 7. No abstract available.

31.

A mouse model to identify cooperating signaling pathways in cancer.

Musteanu M, Blaas L, Zenz R, Svinka J, Hoffmann T, Grabner B, Schramek D, Kantner HP, Müller M, Kolbe T, Rülicke T, Moriggl R, Kenner L, Stoiber D, Penninger JM, Popper H, Casanova E, Eferl R.

Nat Methods. 2012 Sep;9(9):897-900. doi: 10.1038/nmeth.2130. Epub 2012 Aug 5.

PMID:
22863881
32.

Genetically modified mouse models of cancer invasion and metastasis.

Rampetsreiter P, Casanova E, Eferl R.

Drug Discov Today Dis Models. 2011 Fall;8(2-3):67-74. Epub 2011 Jul 1.

33.

The use of bacterial artificial chromosomes for recombinant protein production in mammalian cell lines.

Blaas L, Musteanu M, Grabner B, Eferl R, Bauer A, Casanova E.

Methods Mol Biol. 2012;824:581-93. doi: 10.1007/978-1-61779-433-9_31.

PMID:
22160921
34.

Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma.

Rohr-Udilova N, Sieghart W, Eferl R, Stoiber D, Björkhem-Bergman L, Eriksson LC, Stolze K, Hayden H, Keppler B, Sagmeister S, Grasl-Kraupp B, Schulte-Hermann R, Peck-Radosavljevic M.

Hepatology. 2012 Apr;55(4):1112-21. doi: 10.1002/hep.24808.

PMID:
22105228
35.

JAK-STAT signaling in hepatic fibrosis.

Mair M, Blaas L, Österreicher CH, Casanova E, Eferl R.

Front Biosci (Landmark Ed). 2011 Jun 1;16:2794-811. Review.

PMID:
21622209
36.

p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma.

Schneller D, Machat G, Sousek A, Proell V, van Zijl F, Zulehner G, Huber H, Mair M, Muellner MK, Nijman SM, Eferl R, Moriggl R, Mikulits W.

Hepatology. 2011 Jul;54(1):164-72. doi: 10.1002/hep.24329.

PMID:
21452288
37.

A mouse tool for conditional mutagenesis in ovarian granulosa cells.

Grabner B, Blaas L, Musteanu M, Hoffmann T, Birbach A, Eferl R, Casanova E.

Genesis. 2010 Oct 1;48(10):612-7. doi: 10.1002/dvg.20664.

PMID:
20715176
38.

Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis.

Mair M, Zollner G, Schneller D, Musteanu M, Fickert P, Gumhold J, Schuster C, Fuchsbichler A, Bilban M, Tauber S, Esterbauer H, Kenner L, Poli V, Blaas L, Kornfeld JW, Casanova E, Mikulits W, Trauner M, Eferl R.

Gastroenterology. 2010 Jun;138(7):2499-508. doi: 10.1053/j.gastro.2010.02.049. Epub 2010 Feb 26.

PMID:
20193684
39.

Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis.

Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J, van Zijl F, Schneller D, Esterbauer H, Egger G, Mair M, Kenner L, Mikulits W, Eferl R, Moriggl R, Penninger J, Trauner M, Casanova E.

Hepatology. 2010 Apr;51(4):1319-26. doi: 10.1002/hep.23469.

40.

Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice.

Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L, Poli V, Eferl R.

Gastroenterology. 2010 Mar;138(3):1003-11.e1-5. doi: 10.1053/j.gastro.2009.11.049. Epub 2009 Dec 4.

PMID:
19962983
41.

Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.

van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W.

Oncogene. 2009 Nov 12;28(45):4022-33. doi: 10.1038/onc.2009.253. Epub 2009 Aug 31.

42.

Bacterial artificial chromosomes improve recombinant protein production in mammalian cells.

Blaas L, Musteanu M, Eferl R, Bauer A, Casanova E.

BMC Biotechnol. 2009 Jan 14;9:3. doi: 10.1186/1472-6750-9-3.

43.

Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1.

Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, Idarraga MH, Kenner L, Wagner EF.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10525-30. doi: 10.1073/pnas.0801414105. Epub 2008 Jul 18.

44.

Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia.

Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V, Scheuch H, Priemel M, Stewart CL, Amling M, Wagner EF.

Nature. 2008 Jul 10;454(7201):221-5. doi: 10.1038/nature07019. Epub 2008 Jun 11.

PMID:
18548006
45.

Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease.

Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, Kenner L, Tschachler E, Wagner EF.

Arthritis Res Ther. 2008;10(1):201. doi: 10.1186/ar2338. Epub 2008 Jan 18. Review.

46.

PhiC31-mediated cassette exchange into a bacterial artificial chromosome.

Blaas L, Musteanu M, Zenz R, Eferl R, Casanova E.

Biotechniques. 2007 Nov;43(5):659-60, 662, 664.

PMID:
18072595
47.

Simultaneous generation of fra-2 conditional and fra-2 knock-out mice.

Eferl R, Zenz R, Theussl HC, Wagner EF.

Genesis. 2007 Jul;45(7):447-51.

PMID:
17607691
48.

Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation.

Bakiri L, Takada Y, Radolf M, Eferl R, Yaniv M, Wagner EF, Matsuo K.

Bone. 2007 Apr;40(4):867-75. Epub 2006 Dec 26.

PMID:
17189721
49.

c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity.

Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M, Hui L, Wagner EF.

Genes Dev. 2006 Aug 15;20(16):2306-14.

50.

Fos/AP-1 proteins in bone and the immune system.

Wagner EF, Eferl R.

Immunol Rev. 2005 Dec;208:126-40. Review.

PMID:
16313345

Supplemental Content

Support Center